GlassScriptPhysician profile
David C Lundy
NPI 1881653426
$10,180.72
in general payments reported to CMS, 2019-2025
35 companies · $749 in 2025
The $749 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $638 · 2021: $1,246 · 2022: $2,030 · 2023: $1,608 · 2024: $3,173 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,904 · Travel and Lodging: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,903.95 |
| Travel and Lodging | $626.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,593.12 | 2019-2025 | |
| Gilead Sciences, INC. | $633.47 | 2019-2024 | |
| Stryker Corporation | $626.81 | 2024 | 1788 |
| Genzyme Corporation | $455.77 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $405.86 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $390.76 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $281.17 | 2019-2024 | |
| Evoke Pharma, INC. | $265.07 | 2022-2025 | Gimoti |
| Ardelyx, INC. | $244.28 | 2023-2025 | Ibsrela |
| Ambu INC. | $244.17 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $230.15 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $181.98 | 2023-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.71 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $143.29 | 2023-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $136.80 | 2024 | Stelara, Remicade |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $131.86 | 2023-2025 | Ocaliva |
| Novo Nordisk INC | $110.30 | 2025 | Wegovy |
| Apollo Endosurgery US INC | $107.98 | 2020 | |
| Ironwood Pharmaceuticals, INC | $90.42 | 2019 | |
| Medtronic, INC. | $89.36 | 2024 | Manoscan |
| E.R. Squibb & Sons, L.L.C. | $84.56 | 2021 | |
| Braintree Laboratories, INC. | $82.11 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $73.80 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $65.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $55.89 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $55.40 | 2022 | |
| Pfizer INC. | $44.01 | 2024 | |
| Vivus LLC | $42.26 | 2024 | Qsymia |
| Nestle Healthcare Nutrition INC. | $24.99 | 2023 | |
| Bioventus LLC | $22.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.06 | 2023 | |
| Conmed Corporation | $19.27 | 2023 | Conmed Dilation |
| Alcresta Therapeutics, INC. | $18.34 | 2023 | Relizorb |
| Enterra Medical, INC. | $18.00 | 2024 | |
| Allergan, INC. | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.